title: Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.
abstract: Sodium stibogluconate (SSG, Pentostam) and meglumine antimoniate (MA, Glucantime) are two antimonials that are widely used to treat cutaneous leishmaniasis (CL), but the relative efficacies of these treatments are not clear. The aim of this study is to compare the efficacy of intralesional SSG with intralesional MA therapy in the treatment of CL. One month after completion of the therapy, 1431 of 1728 patients (82%) who received intralesional MA showed complete clinical cure compared to 1157 of 1728 patients (67%) in the SSG group. Patients who did not respond to the first round of therapy were re-administered the same treatment but with twice weekly injections. Following completion of the second course of therapy, 237 of 297 patients (80%) in the MA group and 407 of 561 patients (72%) in the SSG group healed their lesions by 1-month post-treatment. At both times, the differences in cure rates between MA and SSG groups were statistically significant (p < 0.05). Cure rates in the MA group were always significantly higher than SSG groups irrespective of other parameters including age, gender, lesion site and type of lesion. Intralesional MA is more effective than intralesional SSG in the treatment of CL.
authors.affiliation: a Dermatology Clinic, Special Lokman Physician Van Hospital , Van , Turkey .
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Yesilova
authors.affiliation: b Department of Dermatology , Harran University School of Medicine , Şanlıurfa , Turkey .
authors.forename: Hacer Altın
authors.initials: HA
authors.lastname: Surucu
authors.affiliation: c Division of Basic Immunology, Department of Medical Microbiology , Gulhane Military Medical Academy , Ankara , Turkey .
authors.forename: Nurittin
authors.initials: N
authors.lastname: Ardic
authors.affiliation: b Department of Dermatology , Harran University School of Medicine , Şanlıurfa , Turkey .
authors.forename: Mustafa
authors.initials: M
authors.lastname: Aksoy
authors.affiliation: d Department of Biostatistics , School of Medicine, YuzuncuYıl University , Van , Turkey , and.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Yesilova
authors.affiliation: e Department of Microbiology , The Ohio State University Medical Center , Columbus , OH , USA.
authors.forename: Steve
authors.initials: S
authors.lastname: Oghumu
authors.affiliation: e Department of Microbiology , The Ohio State University Medical Center , Columbus , OH , USA.
authors.forename: Abhay R
authors.initials: AR
authors.lastname: Satoskar
mesh_terms: D000293:Adolescent; D000328:Adult; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000967:Antimony Sodium Gluconate
keywords: Cutaneous leishmaniasis; meglumine antimoniate; sodium stibogluconate